{"id":"W4382023148","doi":"10.3390/curroncol30070454","title":"Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Metastatic breast cancer; Aromatase inhibitor; Oncology; Breast cancer; Regimen; Clinical endpoint; Retrospective cohort study; Adverse effect; Progression-free survival; Aromatase; Cancer; Chemotherapy; Randomized controlled trial; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003603733,0.0001792502,0.0004576282,0.0002391764,0.0001449132,0.000207137,0.0002085625,0.0001335407,0.000575377],"category_scores_gemma":[0.0004465005,0.00006536564,0.0002254469,0.0003196543,0.0001274803,0.0001422471,0.0001133863,0.0002978746,0.00008335435],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004629247,"about_ca_system_score_gemma":0.0003568635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005871069,"about_ca_topic_score_gemma":0.002710037,"domain_scores_codex":[0.9998533,0.00003777314,0.0000153326,0.00003414657,0.00004336729,0.00001602139],"domain_scores_gemma":[0.9998444,0.00003252731,0.00006087638,0.0000110985,0.000008316329,0.00004266762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.06658395,0.003980703,0.2581401,0.002512189,0.001746124,0.004947329,0.0002473681,0.00393879,0.1239635,0.0003867575,0.004219797,0.5293334],"study_design_scores_gemma":[0.01438134,0.1684429,0.7182672,0.0003528219,0.002463772,0.02030345,0.0001300781,0.003628115,0.04110691,0.0003424563,0.0305278,0.0000531848],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9777113,0.02033425,0.0003585313,0.0001428121,0.00004359054,0.0001139082,0.0001756853,0.0000201809,0.001099908],"genre_scores_gemma":[0.9952408,0.00373166,0.0004337472,0.0000840424,0.00004534418,0.00003041902,0.0001792638,0.00000192439,0.0002527706],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0005871069,"threshold_uncertainty_score":0.003358722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0781724674039042,"score_gpt":0.4118370089856422,"score_spread":0.333664541581738,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}